Visceral Pain Market Research Report

1
Your Catalyst to a Lucrative Business
Visceral Pain Market Share, Size, Growth Rate,
Regional Outlook, Trends and Forecasts to 2024
Hexa Research
Global Visceral Pain Market Size to Reach USD
14.22 Billion by 2024
11 December 2018, the global Visceral Pain Market
is expected to reach USD 14.22 billion by 2024,
driven by the increasing geriatric population
globally. Increasing prevalence of visceral pain
and rising awareness regarding the same is
projected to drive market growth over the
forecast period.
In 2016, North America held the majority of share
in global visceral pain market owing to the
increasing healthcare expenditure. Additionally,
the high prevalence of Crohns and irritable
bowel is expected to propel the growth of the
market over the projected period.
Asia Pacific is expected to be the fastest
growing region with the CAGR of 6.2. The
increase in the healthcare infrastructure and
presence of a large pool of patients is projected
to drive the demand for the visceral pain
industry during the forecast period.
Analgesic segment dominated the market for the
visceral pain with the market share of 60.4. The
major share of the analgesic segment is
attributed to the increasing penetration of
generic drug. Furthermore, rising healthcare
expenditure and an increasing use of opioids for
the chronic pain are the key factors attributing
to its share.
Browse Details of Report _at_ https//www.hexaresearc
h.com/research-report/visceral-pain-market
Follow Us
2
Your Catalyst to a Lucrative Business
In 2016, Crohns disease was the largest
indication segment for the visceral pain market
contributing to 41.4 of the market share.
Increasing occurrences of Crohns disease across
the globe coupled with the growing drug therapies
for the treatment of the disease are the key
factors attributing to the major
share. Furthermore, increasing awareness about
Crohns disease is fueling the demand for
treatment therapies.
Key market players include Pfizer, Johnson
Johnson, Abbvie, Takeda, Allergan, and
AstraZeneca. These companies are focusing on RD
for visceral pain therapeutics. These companies
are likely to cater their products to patients
affected by visceral pain. The growth of the
geriatric population is expected to help
in augmenting the profits of these companies over
the next few years.
Growing focus on research and development by
pharmaceutical companies and government
initiatives are expected to boost the visceral
pain industry during the forecast period. The
market is projected to witness significant gain
during the forecast period owing to increasing
collaboration within pharmaceutical companies.
Also, factors such as increasing awareness among
people regarding visceral pain are
further anticipated to propel the market growth.
Hexa Research has segmented the global visceral
pain market on the basis of therapeutics,
indications and region
Segmentation by therapeutics, 2014 - 2024 (USD
Million)
Analgesics
Narcotics
NSAID
Pain modifiers Tricyclic Antidepressants
Tricyclic Anticonvulsant Others
Segmentation by indications, 2014 - 2024 (USD
Million)
Interstitial cystitis Crohns
Irritable bowel Chronic prostatitis
Segmentation by region, 2014 - 2024 (USD Million)
Follow Us
3
Your Catalyst to a Lucrative Business
North America Europe
Asia Pacific
Rest of the World (RoW)
Key players analyzed Pfizer Inc.
Allergan
Johnson Johnson Bayer AG
Takeda Pharmaceutical Company Limited
Mallinkrodt Pharmaceuticals AbbVie Inc.
AstraZeneca
Browse Related Category Market Reports _at_
https//www.hexaresearch.com/research-category/cli
nical-diagnostics-industry
Follow Us
4
Your Catalyst to a Lucrative Business
Table of Content of Visceral Pain Market
Chapter 1. Market Summary
1.1. Market trends movement
Chapter 2. Visceral Pain Market Trends Drivers
Opportunities 2.1. Introduction
2.2. Key industry trends
2.3. Market drivers
2.4. Market restraints
2.5. Value chain analysis 2.6. Porter's Five
Forces analysis 2.7. SWOT
2.8. Regulatory framework
Chapter 3. Visceral Pain Market Trends, By
Therapeutics 3.1. Global visceral pain market
movement, by therapeutics, 2014 2024 3.2.
Analgesic
3.2.1. Market estimates and forecast, 2014 2024
(USD Million) 3.2.2. Market estimates and
forecast, by product, 2014 2024 (USD
Million) 3.2.2.1. Narcotics
3.2.2.1.1. Market estimates and forecast, 2014
2024 (USD Million) 3.2.2.2. NSAID
3.2.2.2.1. Market estimates and forecast, 2014
2024 (USD Million) 3.3. Pain Modifiers
3.3.1. Market estimates and forecast, 2014 2024
(USD Million) 3.3.2. Market estimates and
forecast, by product, 2014 2024 (USD
Million) 3.3.2.1. Tricyclic Antidepressants
3.3.2.1.1. Market estimates and forecast, 2014
2024 (USD Million) 3.3.2.2. Tricyclic
Anticonvulsant
3.3.2.2.1. Market estimates and forecast, 2014
2024 (USD Million) 3.4. Others
3.4.1. Market estimates and forecast, 2014 2024
(USD Million)
Chapter 4. Visceral pain Market Trends, By
indications
4.1. Global visceral pain market movement, by
indications, 2014-2024
Follow Us
5
Your Catalyst to a Lucrative Business
4.2. Interstitial cystitis
4.2.1. Market estimates and forecast, 2014 2024
(USD Million) 4.3. Crohns
4.3.1. Market estimates and forecast, 2014 2024
(USD Million) 4.4. Irritable bowel
4.4.1. Market estimates and forecast, 2014 2024
(USD Million) 4.5. Chronic prostatitis
4.5.1. Market estimates and forecast, 2014 2024
(USD Million)
Chapter 5. Visceral pain Market Trends, By Region
5.1. Global visceral pain market movement, by
region, 2014 2024 5.1.1. North America
5.1.1.1. Market estimates and forecast, 2014
2024 (USD Million) 5.1.1.2. Market estimates and
forecast, by therapeutic class, 2014 2024 (USD
Million) 5.1.1.2.1. Market estimates and
forecast, by analgesics, 2014 2024 (USD
Million) 5.1.1.2.2. Market estimates and
forecast, by pain modifiers, 2014 2024 (USD
Million) 5.1.1.3. Market estimates and forecast,
by indications, 2014 2024 (USD Million) 5.1.2.
Europe
5.1.2.1. Market estimates and forecast, 2014
2024 (USD Million) 5.1.2.2. Market estimates and
forecast, by therapeutic class, 2014 2024 (USD
Million) 5.1.2.2.1. Market estimates and
forecast, by analgesics, 2014 2024 (USD
Million) 5.1.2.2.2. Market estimates and
forecast, by pain modifiers, 2014 2024 (USD
Million) 5.1.2.3. Market estimates and forecast,
by indications, 2014 2024 (USD Million) 5.1.3.
Asia Pacific
5.1.3.1. Market estimates and forecast, 2014
2024 (USD Million) 5.1.3.2. Market estimates and
forecast, by therapeutic class, 2014 2024 (USD
Million) 5.1.3.2.1. Market estimates and
forecast, by analgesics, 2014 2024 (USD
Million) 5.1.3.2.2. Market estimates and
forecast, by pain modifiers, 2014 2024 (USD
Million) 5.1.3.3. Market estimates and forecast,
by indications, 2014 2024 (USD Million) 5.1.4.
RoW
5.1.4.1. Market estimates and forecast, 2014
2024 (USD Million) 5.1.4.2. Market estimates and
forecast, by therapeutic class, 2014 2024 (USD
Million) 5.1.4.2.1. Market estimates and
forecast, by analgesics, 2014 2024 (USD
Million) 5.1.4.2.2. Market estimates and
forecast, by pain modifiers, 2014 2024 (USD
Million) 5.1.4.3. Market estimates and forecast,
by indications, 2014 2024 (USD Million)
Follow Us
6
Your Catalyst to a Lucrative Business
Chapter 6. Competitive Landscape
6.1. Competitive landscape analysis, 2016 6.2.
Strategic framework
6.3. Potential customer base concentration 6.4.
Company market positioning 6.5. Company profiles
6.5.1. Pfizer Inc.
6.5.1.1. Company Overview 6.5.1.2. Product
Benchmarking 6.5.1.3. Financial
Performance 6.5.1.4. Recent Initiatives
6.5.2. Allergan
6.5.2.1. Company Overview 6.5.2.2. Product
Benchmarking 6.5.2.3. Financial
Performance 6.5.2.4. Recent Initiatives
6.5.3. Johnson Johnson
6.5.3.1. Company Overview 6.5.3.2. Product
Benchmarking 6.5.3.3. Financial
Performance 6.5.3.4. Recent Initiatives
6.5.4. Bayer AG
6.5.4.1. Company Overview 6.5.4.2. Product
Benchmarking 6.5.4.3. Financial
Performance 6.5.4.4. Recent Initiatives
6.5.5. Takeda Pharmaceutical Company
Limited 6.5.5.1. Company Overview 6.5.5.2.
Product Benchmarking 6.5.5.3. Financial
Performance 6.5.5.4. Recent Initiatives
6.5.6. Mallinkrodt Pharmaceuticals 6.5.6.1.
Company Overview 6.5.6.2. Product
Benchmarking 6.5.6.3. Financial
Performance 6.5.6.4. Recent Initiatives
Follow Us
7
Your Catalyst to a Lucrative Business
6.5.7. AbbVie Inc.
6.5.7.1. Company Overview 6.5.7.2. Product
Benchmarking 6.5.7.3. Financial
Performance 6.5.7.4. Recent Initiatives 6.5.8.
AstraZeneca
6.5.8.1. Company Overview 6.5.8.2. Product
Benchmarking 6.5.8.3. Financial
Performance 6.5.8.4. Recent Initiatives 6.5.9.
List of other vendors
Chapter 7. Methodology and Scope 7.1. Research
methodology
7.2. Research Scope Assumptions 7.3. List of
data sources
Follow Us
8
Your Catalyst to a Lucrative Business
About Us
Hexa Research is a market research and consulting
organization, offering industry reports, custom
research and consulting services to a host of key
industries across the globe. We offer
comprehensive business intelligence in the form
of industry reports which help our clients obtain
clarity about their business environment and
enable them to undertake strategic growth
initiatives.
Contact Us
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018 United States
Phone [phone] Email sales_at_hexaresearch.c
om Website - https//www.hexaresearch.com
Follow Us